Unlocking Future Insights in Biomedicine Research & Development

12 - 14 March 2025
London, UK

Move as one.

Together, we can accelerate life-saving treatments, sustainably and at scale.

NextGen Biomed is the biologics drug development meeting point — uniting six longstanding industry communities on one platform.

Through our events and channels we enable more than 30,000 biologics and immunotherapy R&D experts to build partnerships, align specialisms, bridge unknowns and commercially convert novel cures into life-changing outcomes for patients.

Hear from past attendees of last year's Biologics 2024 conference

Explore the NextGen Biomed 2025 Programme

Antibody Society

NextGen Biomed 2025 is supported by our
Scientific Programme Partner The Antibody Society

NextGen Biomed Square

About

Discover more about our ecosystem of channels for the biologics R&D community

Attend Image

Attend

Be part of the new wave of Biomed R&D innovation

Partner Image

Partner

Showcase your offering to leading pharma and biotech decision makers

Whats On Image

What's On

Explore dynamic panels, engaging roundtables, and hands-on workshops

NextGen Biomed 2025 Programme Highlights

Explore dynamic panels, engaging roundtables, and hands-on workshops designed to drive innovation and foster collaboration, including:

Proteins, Antibodies & ADCs
Panel Discussion: What Is The Next Game Changer In Antibody Engineering?

Moderator: Karen Silence, Head Preclinical Product Development, ArgenX
Panellists include Berit Olsen Krogh, Senior Research Fellow; and Lundbeck Andrew Buchanan, Principal Scientist, AstraZeneca

Peptides
Roundtable: Regulatory Insights On Bringing A Peptide To Human Trials

Moderator: Paul Reid, Co-Founder & Chief Scientific Officer, Celtic Bio

Oligonucleotides
Workshop: Development Of Targeted Delivery Systems

Two Presentations, followed by a Panel Discussion on 'The Next Chapter Of Oligonucleotide Delivery'
Moderator: Steve Hood, Senior Director, Oligonucleotide ADME Strategy, GSK

Sustainability in Tides & Biologics
Panel Discussion: Navigating The Paradigm Shift Towards Greener Approaches

Moderator: Walter Cabri, Full Professor of Organic Chemistry, University of Bologna
Panellists include Daniel Sejer Pedersen, Chemical Development Specialist CMC API Development, Novo Nordisk;
Anna Maria Papini, Full Professor & Group Leader, University of Florence;
Louis Diorazio, Senior Principal Scientist, New Modalities, AstraZeneca;
Alessandra Tolomelli, Associate Professor, University of Bologna

Immunotherapy & Immuno-oncology
Presentation: How The RNA Technologies Could Help To Prevent Infectious Diseases And Could Be Applied To Various Chronic Disease Immunotherapies?

Presented by: Daniel Larocque, Innovation Lead, Innovation and Emerging Science, Sanofi

Key Event Highlights

An unmissable journey awaits you: from celebrated keynote speakers and insightful fireside chats, to an exclusive gala dinner at London's Science Museum. Discover the moments that will transform your NextGen Biomed experience. 

Who is Speaking at NextGen Biomed 2025?

Anna Perdrix
Founder & Co-Chief Executive Officer,
Sixfold Bioscience
Fernando Albericio
Professor,
University of KwaZulu-Natal
Joel Richard
Chief Development Officer,
Enterome
Kelly Loyet
Distinguished Scientist,
Genentech
Livija Deban
Chief Scientific Officer,
Prokarium
Maria Koufali
Director,
UK Vaccine Innovation Pathway
Marta Amaral
Group Head High Throughput Protein Engineering in Large Molecules Research,
Sanofi
Martina Ochs
Project Leader,
CEPI
Philip Beer
Chief Scientific Officer,
Step Pharma
Rick Hibbert
Vice President & Head of CMC Science & Technologies,
Genmab
Sudhir Agrawal
President & Founder,
ARNAY Sciences
Tristan Vaughan
Vice President Protein Engineering,
Immunocore
Aaron John Balana
Scientist III,
Genentech
Aikaterini Gatsiou
Assistant Professor,
Lancaster University
Ajan Reginald
Chief Executive Officer,
Roquefort THerapeutics PLC
Alain Wagner
Director,
Strasbourg University
Alastair Lawson
Vice President and Immunology Fellow,
UCB
Alessandra Tolomelli
Associate Professor,
University of Bologna
Alessandro Gori
Group leader,
National Research Council of Italy
Alexandria Cogdill
Head of Strategic Initiatives, Global Business Development,
Daiichi Sankyo, Inc
Alexey Rak
Head of Bio Structure and Biophysics,
Sanofi
Álvaro Enríquez García
Medicinal chemist,
Eli Lilly
Amita Vaidya
Principal Scientist,
Sanofi
Ammar Ahmed
Senior Scientist,
Imperial College London
Amy Li
Director, Drug Discovery,
T-Therapeutics Ltd
Andreas Reichel
Vice President, Head PMS,
Bayer AG
Andreas Midbøe Hoff
Head of In Silico & AI Department,
Nykode
Andrew Slee
Chief Operating Officer,
Protagenic Therapeutics
Andrew Jamieson
Professor,
University of Glasgow
Andrew Buchanan
Scientist,
AstraZeneca
Andri Vasou
Senior Research Scientist,
Bioarchitech
Aneesh Karatt-Vellatt
CoFounder & CSO,
Maxion therapeutics
Anna Hine
Professor of Protein Engineering,
Aston University
Anna Maria Papini
Full Professor and Group leader of PeptLab,
University of Florence (Italy)
Annelise Vuidepot
Chief Technology Officer,
Immunocore
Ash Otter
Principal Investigator, Emerging Pathogen Serology,
UKHSA
Baldur Sveinbjørnsson
Chief Scientific Officer,
Lytix Biopharma
Bassam Hallis
Deputy Director of Research and Evaluation,
ukhsa.gov.uk
Benjamin Lindner
Data Scientist,
Boehringer Ingelheim RCV GmbH & Co KG
Berit Olsen Krogh
Senior Research Fellow,
Lundbeck
Bernard Maillere
Head of laboratory,
CEA
Bjorn Onfelt
Professor of Applied Physics,
Royal Institute of Technology
Brian Schanen
Global Head,
Sanofi
Bryce Nelson
Head Protein and Antibody Engineering,
Orion
Callum Scott
Head of Development,
Scancell
Carla Vinals
Vice President, Global Regulatory Product Strategy,
Moderna Therapeutics
Carol Sze Ki Leung
Senior Immunologist,
Ludwig Institute, Oxford University
Caroline Lonez
R&D Associate Director,
Celyad
Charlotte Vernhes
Scientific and Medical Affairs Director,
Vaccines Europe
Chris Hart
Chief Executive Officer,
Creyon Bio
Christian Garde
Director,
Evaxion Biotech
Christopher Scott
Professor,
Queen's University Belfast
Christopher Coxon
Senior Lecturer, Medicinal Chemistry,
THE UNIVERSITY OF EDINBURGH
Dan Swerdlow
Senior Director,
GSK
Dan Hardy
Chief Executive Officer,
Microsol Ltd
Daniel Larocque
Innovation Leader,
Sanofi Vaccines
Daniel Fonseca
Senior Scientist,
Immunocore
Daniel Sejer Pedersen
Specialist,
Novo Nordisk A/S
Darko Skegro
Associate Director,
Novartis
David Craik
Professor,
The University of Queensland
David Evans
Chief Scientific Officer,
Sirnaomics
David Brockwell
Professor,
University of Leeds
David Pejoski
Cofounder, Co-CEO, COO, Board Member,
Adoram Therapeutics
David Wraith
Professor of Immunology, Director of the Institute of Immunology and Immunotherapy,
University of Birmingham
Denise Steckel
Head of Clinical Collaborations Development,
Genentech
Ed Tate
Professor,
Imperial College London
Eef Dirksen
Group Leader,
Byondis B.V.
Elisa Marelli
Research Scientist,
Scancell
Emma Grant
Senior Analytical Development Scientist,
Immunocore
Emma Stanley
Director, Program Lead - Head of Antibody Discovery,
Mestag Therapeutics
Erik Vernet
Vice President - Scientific Data Registration,
Novo Nordisk
Fazel Shabanpoor
Lab Head Peptide And Oligonucleotide Therapeutics,
The Florey Institute of Neuroscience and Mental Health
Felix Schumacher
Program Leader Targeted Therapeutics,
Hoffmann La Roche Ltd
Francisca Wollerton
Senior Director of Protein Engineering and Novel Modalities,
AstraZeneca
Gabriel Wong
Senior Director Physician, Clinical Research, Immunology,
AstraZeneca
Gal Gur
VP Business Development,
Anima Biotech
Georgios Skretas
Director, Institute for Bioinnovation,
Biomedical Sciences Research Center "Alexander Fleming"
Giulio Russo
Senior Scientist,
Merus NV
Hans Melo
Chief Executive Officer,
Menten Biotechnology Labs
Hans Van Der Vliet
Chief Scientific Officer,
LAVA Therapeutics
Helen Bright
Chief Scientific Officer,
Centauri Therapeutics
Helene Kaplon
Translational Scientist,
Servier
Henry Maun
Staff Scientist,
Genentech
Hester Van Zeeburg
PM immunomonitoring,
Mendus AB
Ian Hamley
Professor of Physical Chemistry,
University of Reading
Ijeoma Uchegbu
Professor of Pharmaceutical Nanoscience,
University College London
Immanuel Lerner
Chief Executive Officer,
Pepticom
Isabelle Sermadiras
Associate Principal Scientist,
AstraZeneca
Iulia Oita
CMC manager,
Ziphius Vaccines
Janos Tibor Kodra
Principal Scientist,
Novo Nordisk
Jean Ge
Patent Attorney,
Wolf Greenfield
Jenny Fitting
Head of AAV and Protein Science,
Bayer
John Maher
Chief Scientific Officer,
Leucid Bio
Jonathan Kwok
Chief Executive Officer,
Infinitopes
Joost Uitdehaag
Head of Biology,
Crossfire Oncology
Jörg Wischhusen
Professor,
University Hospital Würzburg
Jutta Eichler
Professor,
University of Erlangen-Nurnberg
Karen Silence
Head Preclinical Product Development,
Argenx BVBA
Kate Smith
Senior Director, Head of UK Protein and Cell Sciences,
GSK
Kerry Chester
Professor,
UCL
Kevin Fitzgerald
Chief Scientific Officer,
Epsilogen
Kevin Maskell
Research Director,
Bioarchitech
Kirsty Crame
Vice President Clinical Strategy & Development,
Medigene AG
Knud Jørgen Jensen
Professor,
Copenhagen University
Komal Kedia
Associate Principal Scientist,
Merck US
Kuda Muchandibaya
Lecturer for Supply Chain Management & Logistics,
Rhine-Waal University of Applied Sciences
Laura Starkie
Director,
UCB
Laura Collins
Director Bioinformatics,
Immunocore
Leonardo De Maria
Principal Scientist,
AstraZeneca
Louis Diorazio
Senior Principal Scientist,
AstraZeneca
Lucia Ferrazzano
Junior Assistant Professor,
University of Bologna
Luis Gómez-Morales
Scientific Project Manager,
Pepkon
Mads Hald Andersen
Professor, VP,
IO Biotech
Malin Lemurell
Executive Director & Head of Medicinal Chemistry CVRM Biopharmaceuticals R&D,
AstraZeneca
Mani Mudaliar
Director, Quantitative Biomarkers,
Exscientia
Marc Vendrell
Professor of Translational Chemistry,
University of Edinburgh
Maria Fawaz
Associate Principal Scientist,
Merck & Co., Inc., Kenilworth, New Jersey, U.S.A.
Maria DeBruin
Director, Analytical Research and Development,
MSD
Marie McAvoy
Chief Scientific Officer,
Nanosyrinx
Marina Fedorova
Scientific Investigator,
GSK
Mark Eccleston
Chief Executive Officer,
ValiRx Plc.
Mathieu Cinier
Scientific Director,
Affilogic
Matthew Burrell
Associate Director,
AstraZeneca
Mattias Malm
Senior Scientist,
Ferring Pharmaceuticals
Micaela Graglia
Analytical Chemist, Molecular Design,
Silence Therapeutics
Michael Dyson
Vice President,
Ichnos SA
Michael Delaney
Principal Scientist,
NovoNordisk
Michal Shoshan
Founder & Chief Executive Officer,
metaLead Therapeutics AG
Mihaela Bozic
Scientist,
T-Therapeutics
Mikhail Kuravskiy
Principal Scientist,
UCB
Morten Lindow
RNAHub Founder & Mission Lead,
Roche
Nadim Akhtar
Senior Principal Scientist, New Modalities,
AstraZeneca
Nazneen Dewji
Chief Executive Officer,
Cenna Biosciences
Nesrine Chakroun
Associate Director,
Merus NV
Norbert Furtmann
Sanofi,
Head of AI Innovation NANOBODY® Platform
Obinna Ubah
Principal Scientist,
Elasmogen Limited
Owen Vickery
Associate Principal Scientist in augmented biologics,
Astrazeneca
Patricia Alves
Head of the Sanofi Satellite Lab & Coordinator of Analytical Services Unit and Mass Spectrometry Unit,
Instituto de Biologia Experimental e Tecnológica
Paul Wassmann
Senior Principal Scientist,
Novartis AG
Paul Reid
Chief Scientific Officer,
Celtic Biotech
Paul Skipp
Professor of Proteomics,
University of Southampton
Pawel Stocki
Vice President R&D,
Ossianix
Pete Gough
Chief Scientific Officer,
Nimble Therapeutics
Peter Ellmark
CSO,
Alligator Bioscience
Peter Sondermann
CEO,
Tacalyx GmbH Privacy Policy Imprint
Prasun Chakraborty
Chief Executive Officer and Founder,
Genevation LTD
Rajika Perera
Chief Executive Officer,
Poseidon LLC
Raymond Tesi
President & Chief Executive Officer,
InMune Bio
Reeta Daswani
Senior Scientist,
Sixfold
Rita Martello
Scientific Director, NBE DMPK Lead,
Merck KGaA
Rodrigo Abreu
Principal Scientist,
LifeArc
Sagar Kathuria
Biophysicist - Protein Engineering,
Sanofi
Sandeep Talapatra
Science Lead - Protein Science,
GSK
Sandor Batkai
Co-founder, Head of Medical Research and Intelligence,
Cardior Pharmaceuticals GmbH
Sandra Tremmel
Microbiology Engineer, Pharma Technical Product Quality- Analytical Sciences,
F. Hoffmann-La Roche Ltd
Sandrien Janssens
CMC Director,
Mosanna Therapeutics
Santiago Parpal
Principal Scientist,
Sprint Bioscience
Sara Mangsbo
Chief Innovation Officer,
Ultimovacs
Sarah Stuart
HTC Team Leader,
GSK
Sarah Hindson
Senior Scientist,
GSK
Saul Martinez Montero
Senior Director, RNA Therapeutics,
Dyne Therapeutics
Saurabh Sen
Associate Director, Cell Line Development, Mammalian Platform Biologics,
Sanofi
Simon Krah
Associate Director,
Merck Healthcare KgaA
Simon Plyte
Chief Scientific Officer,
Biomunex Pharmaceuticals
Simon Hufton
Section Head Molecular Immunology, Division of Biotherapeutics,
MHRA
Simone Friedrich
Director Antibody Discovery & Development,
iOmx Therapeutics
Sonia Macia
Chief Medical Officer,
Aromics Therapeutics
Sophia Karagiannis
Professor of Translational Cancer Immunology and Immunotherapy,
King's College London
Sritama Bose
Head of Chemistry Research and Innovation,
Nucleic Acid Therapy Accelerator MRC
Stefan Z
Senior Director - Global Head of Antibody Discovery & Protein Engineering,
Merck Kgaa Darmstadt Germany
Stephen Miller
Principal Scientist,
Genentech
Steve Hood
Senior Director, Oligonucleotide ADME Strategy, DMPK,
GSK
Steven Schmitt
Co-Founder & Chief Executive Officer,
Myria Biosciences
Stine Friis Thorsen
Director Clinical Development,
Evaxion Biotech
Sue Charlton
Head of Clinical Evaluation,
UKHSA
Talip Ucar
Senior Director - AI Research,
AstraZeneca
Tatyana Ponomaryov
Principal Scientist,
Plasticell Limited
Thomas Kraft
Principal Scientist,
Roche
Tim Hickling
Immunogenicity Expert Scientist,
Roche
Tomáš Hanke
Professor,
University of Oxford
Tomasz Witkos
Associate Director,
AstraZeneca
Trevor Smith
Vice President,
Inovio
Vaios Karanikas
Biomarker Experimental Medicine Leader, Oncology,
Hoffmann La Roche Ltd
Vincent Dewar
Head of Immunoassay,
GSK
Vincenzo de Filippis
Associate Professor Biochemistry,
University of Padova
Vladimir Gligorijević
Senior Director, AI/ML,
Genentech
Walter Cabri
Professor,
University of Bologna
Wen Chang
Associate Vice President Discovery and Early Development,
AcuraStem
Will Nesbit
Director - Process Chemistry, CMC,
Bicycle Therapeutics
Wolfgang Koch
Senior Scientist,
F-star Therapeutics Inc
Xiao Wan
Senior Researcher - Biology,
Nucleic Acid Therapy Accelerator (NATA)
Yann Abraham
Associate Director AI for Single Cell,
Johnson & Johnson Innovative Medicine
Yi Yang
Principal Scientist,
Ferring Pharmaceuticals A/S
Zahra Rattray
Senior Lecturer,
University of Strathclyde
GenScript

The 1-2-1s are the best thing about Oxford Global events, well organised and good number of relevant contacts. Good high level contacts from big companies.

 

Advanced Therapies Specialist Team Leader,
Genscript

Biosystems Acro

Biologics 2024 has been one of the best events I have attended so far in my career.

 

Territorial Sales Manager UK,
ACROBiosystems Co., Ltd.

Bioassay

 

Impressed by the effort to bring people together.

 

Business Development Director,

Bioassay

IpA

 

Nice set-up, with good support for exhibitors

 

Director of Client Relations,

ImmunoPrecise

Interested in Sponsoring NextGen Biomed?

Become a driving force in accelerating the next generation of biologics and immunotherapy medicines to patients. NextGen Biomed offers a unique platform to enhance your brand visibility and connect with thousands of pharma, biotech, and R&D experts. Our branded event opportunities, immersive experiences, and content services enable you to engage, educate, and collaborate with the community shaping the future of biomedicine today.

Interested in Sponsoring NextGen Biomed?

Become a driving force in accelerating the next generation of biologics and immunotherapy medicines to patients. NextGen Biomed offers a unique platform to enhance your brand visibility and connect with thousands of pharma, biotech, and R&D experts. Our branded event opportunities, immersive experiences, and content services enable you to engage, educate, and collaborate with the community shaping the future of biomedicine today.

2025 Sponsors Include

Register Now

Be part of the new wave of Biomed R&D innovation

Partner with us

Become a driving force in accelerating the next generation of biologics and immunotherapy medicines to patients